CClinicalTrials.gg
Status unknownNCT01009710Updated Jan 18, 2017

Measured Hypocretin Levels and Recovery After Hip Surgery

An observational study in Osteoarthritis, Hip, sponsored by Stanford University. Status unknown at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-18.

Sponsored by Stanford University · Observational

The sponsor has not verified this record recently (last verified Jan 2017), so the status shown — last known as Active, not recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Study summary

A specific group of neurons in the brain produces hypocretin, a peptide which has been established as an important regulator of sleep and wakefulness. Activation of these neurons (increased hypocretin) stabilizes wakefulness; impairing or blocking these neurons (decreased hypocretin) promotes sleep. Evidence suggests that these neurons may be involved in the hypnotic properties of several anesthetics, and play a role in the induction and emergence from anesthesia. In humans there is a considerable inter-individual variability in hypocretin levels. This study aims to investigate how hypocretin levels affect the anesthetic care and recovery of patients undergoing elective hip surgery.

02

Conditions studied

  • Osteoarthritis, Hip

Browse trials for

03

In context

Osteoarthritis, Hip

628 studies on the registry are indexed under Osteoarthritis, Hip; 121 are open to participants now.

This study's planned enrollment of 50 is below the median of 141 across 154 observational studies indexed under Osteoarthritis, Hip.

Browse Osteoarthritis, Hip studies →

Lead sponsor

Stanford University is the lead sponsor of 2,117 studies on the registry; 425 are open to participants now.

Of its 259 completed or terminated interventional studies of FDA-regulated products, 197 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients scheduled for elective total hip arthroplasty through the Stanford Orthopedic Clinic.

Eligibility criteria

Inclusion Criteria:- Adult (18 years of age or older)

  • Male or female
  • Scheduled for elective total hip arthroplasty at the Stanford Orthopedic Clinic.
  • Comprehend spoken and written English Exclusion Criteria:- ASA physical status > III (patients with severe systemic disease)
  • Diagnosed psychiatric disease (except mild depression)
  • Any diagnoses CNS disease or dementia
  • History of stroke
  • History of untreated thyroid disease
  • Difficulty in airway management (ventilation and/or intubation)
  • Body Mass Index (BMI) > 35 kg/m2
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
50 participants (estimated)
06

What researchers measure

Primary outcomes

  1. Anesthetic Recovery Times

    recovery from anesthesia will be measured by short-term outcomes like time to tracheal extubation and response to verbal commands, as well as by psycho-vigilance testing up to 72 hours postoperatively

    Time frame: 0-72 hours after surgery

Secondary outcomes

  1. sensitivity to sevoflurane during inhalation induction to anesthesia, determined by bispectral index of the EEG

    pharmacodynamic analysis of bispectral index of the EEG response to sevoflurane

    Time frame: during anesthetic induction

  2. pain and sleepiness

    assessment of pain and sleepiness using the numerical rating scale (0-10) during the 72 hours postoperatively

    Time frame: from 0-72 hours after surgery

07

Study locations

1 site
  • Stanford University School of Medicine
    Stanford, California 94305, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01009710
Lead sponsor
Stanford University
Responsible party
Anthony Doufas (MD, PhD, Stanford University) — Principal investigator
First posted
Nov 9, 2009
Start date
Jul 2009
Primary completion
Dec 2013
Completion
Dec 2018 (estimated)
Last update
Jan 18, 2017

Study contacts

Anthony Doufas
principal investigator · Stanford University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion